{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:39:38Z","timestamp":1789007978736,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012990","name":"Universit\u00e0 degli Studi di Siena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012990","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a recently described pathological entity. It is an acquired monogenic autoinflammatory disease caused by somatic mutations of the <jats:italic>UBA1<\/jats:italic> gene in blood cells precursors; the gene encodes one of the two E1 enzyme isoforms that initiates ubiquitylation in cell\u2019s cytoplasm. VEXAS syndrome leads to systemic inflammation, with all organs and tissues potentially involved. The clinical picture may be extremely heterogenous, mimicking different other systemic rheumatologic entities coexisting with haematological disorders, especially myelodysplastic syndrome. This new disease represents a very intriguing clinical condition in several respects: it accounts for the paradigm of adult-onset monogenic autoinflammatory diseases determined by a genetic mosaicism resulting in the development of a challenging multiorgan inflammatory condition. Moreover, VEXAS syndrome is perhaps not an exceptionally rare condition and represents an example of a systemic genetic autoinflammatory disease drawing its origin in bone marrow disorders. VEXAS syndrome should be strongly considered in each adult patient with an unexplained systemic inflammatory condition, especially when recurrent fevers, neutrophilic dermatosis, relapsing polychondritis, ocular inflammation and other systemic inflammatory symptoms accompanying myelodysplastic syndrome or other haematological disorders. The syndrome deserves a multidisciplinary approach to reach the diagnosis and ensure the best management of a potentially very challenging condition. To quickly describe the clinical course, long-term outcomes, and the optimal management of this new syndrome it is essential to join forces internationally. To this end, the international AutoInflammatory Disease Alliance (AIDA) registry dedicated to VEXAS syndrome has been developed and is already active.<\/jats:p>","DOI":"10.1007\/s11739-023-03193-z","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T22:06:26Z","timestamp":1674252386000},"page":"711-722","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases"],"prefix":"10.1007","volume":"18","author":[{"given":"Antonio","family":"Vitale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Caggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bimonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Caroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Marco","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Fabbiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Renieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Fabiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7352-1275","authenticated-orcid":false,"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"key":"3193_CR1","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","volume":"383","author":"DB Beck","year":"2020","unstructured":"Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W et al (2020) Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 383:2628\u20132638. https:\/\/doi.org\/10.1056\/NEJMoa2026834","journal-title":"N Engl J Med"},{"key":"3193_CR2","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3324\/haematol.2021.280238","volume":"107","author":"RJ Stubbins","year":"2022","unstructured":"Stubbins RJ, McGinnis E, Johal B, Chen LY, Wilson L, Cardona DO et al (2022) VEXAS syndrome in a female patient with constitutional 45, X (Turner syndrome). Haematologica 107:1011\u20131013. https:\/\/doi.org\/10.3324\/haematol.2021.280238","journal-title":"Haematologica"},{"key":"3193_CR3","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s10875-022-01258-w","volume":"42","author":"J Poulter","year":"2022","unstructured":"Poulter J, UKGCA\/VEXAS Consortium, Morgan A, Cargo C, Savic S (2022) A high-throughput amplicon screen for somatic UBA1 variants in cytopenic and giant cell arteritis cohorts. J Clin Immunol 42:947\u2013951. https:\/\/doi.org\/10.1007\/s10875-022-01258-w","journal-title":"J Clin Immunol"},{"key":"3193_CR4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/hmg\/5.3.391","volume":"5","author":"L Carrel","year":"1996","unstructured":"Carrel L, Clemson CM, Dunn JM, Miller AP, Hunt PA, Lawrence JB et al (1996) X inactivation analysis and DNA methylation studies of the ubiquitin activating enzyme E1 and PCTAIRE-1 genes in human and mouse. Hum Mol Genet 5:391\u2013401. https:\/\/doi.org\/10.1093\/hmg\/5.3.391","journal-title":"Hum Mol Genet"},{"key":"3193_CR5","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/bjd.20805","volume":"186","author":"S Georgin-Lavialle","year":"2022","unstructured":"Georgin-Lavialle S, Terrier B, Guedon AF, Heiblig M, Comont T, Lazaro E et al (2022) Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients. Br J Dermatol 186:564\u2013574. https:\/\/doi.org\/10.1111\/bjd.20805","journal-title":"Br J Dermatol"},{"key":"3193_CR6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/mrcr\/rxab021","volume":"6","author":"F Shaukat","year":"2022","unstructured":"Shaukat F, Hart M, Burns T, Bansal P (2022) UBA1 and DNMT3A mutations in VEXAS syndrome. A case report and literature review. Mod Rheumatol Case Rep 6:134\u2013139. https:\/\/doi.org\/10.1093\/mrcr\/rxab021","journal-title":"Mod Rheumatol Case Rep"},{"key":"3193_CR7","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1182\/blood.2022016985","volume":"140","author":"MA Ferrada","year":"2022","unstructured":"Ferrada MA, Savic S, Ospina Cardona D, Collins JC, Alessi H, Gutierrez-Rodrigues F et al (2022) Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis. Blood 140:1496\u20131506. https:\/\/doi.org\/10.1182\/blood.2022016985","journal-title":"Blood"},{"key":"3193_CR8","doi-asserted-by":"publisher","first-page":"e371","DOI":"10.1093\/rheumatology\/keac356","volume":"61","author":"JS Topilow","year":"2022","unstructured":"Topilow JS, Ospina Cardona D, Beck DB, Ferrada MA, McMahan ZH, Paik JJ (2022) Novel genetic mutation in myositis-variant of VEXAS syndrome. Rheumatology (Oxford) 61:e371\u2013e373. https:\/\/doi.org\/10.1093\/rheumatology\/keac356","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"3193_CR9","doi-asserted-by":"publisher","first-page":"e661","DOI":"10.1097\/HS9.0000000000000661","volume":"5","author":"MHGP Raaijmakers","year":"2021","unstructured":"Raaijmakers MHGP, Hermans M, Aalbers A, Rijken M, Dalm VASH, van Daele P et al (2021) Azacytidine treatment for VEXAS syndrome. Hemasphere 5(12):e661. https:\/\/doi.org\/10.1097\/HS9.0000000000000661","journal-title":"Hemasphere"},{"issue":"16","key":"3193_CR10","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1182\/bloodadvances.2021004976","volume":"5","author":"IE Obiorah","year":"2021","unstructured":"Obiorah IE, Patel BA, Groarke EM, Wang W, Trick M, Ombrello AK et al (2021) Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. Blood Adv 5(16):3203\u20133215. https:\/\/doi.org\/10.1182\/bloodadvances.2021004976","journal-title":"Blood Adv"},{"key":"3193_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41584-020-00559-x","volume":"17","author":"S Onuora","year":"2021","unstructured":"Onuora S (2021) Somatic mutations cause VEXAS syndrome. Nat Rev Rheumatol 17:1. https:\/\/doi.org\/10.1038\/s41584-020-00559-x","journal-title":"Nat Rev Rheumatol"},{"key":"3193_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-022-00866-5","author":"V Jachiet","year":"2022","unstructured":"Jachiet V, Ricard L, Hirsch P, Malard F, Pascal L, Beyne-Rauzy O et al (2022) MINHEMON: French Network of dysimmune disorders associated with hemopathies. Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases. Clin Exp Med. https:\/\/doi.org\/10.1007\/s10238-022-00866-5","journal-title":"Clin Exp Med"},{"key":"3193_CR13","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1093\/rheumatology\/keac371","volume":"62","author":"B Lucchino","year":"2022","unstructured":"Lucchino B, Finucci A, Ghellere F, Bortolotti ME, Tedesco A, Lombardi S (2022) Influence of HLA polymorphisms on clinical features of VEXAS syndrome: a potential epistatic mechanism. Rheumatology (Oxford) 62:e7\u2013e8. https:\/\/doi.org\/10.1093\/rheumatology\/keac371","journal-title":"Rheumatology (Oxford)"},{"key":"3193_CR14","doi-asserted-by":"publisher","first-page":"108996","DOI":"10.1016\/j.clim.2022.108996","volume":"238","author":"H Matsumoto","year":"2022","unstructured":"Matsumoto H, Asano T, Tsuchida N, Maeda A, Yoshida S, Yokose K et al (2022) Beh\u00e7et\u2019s disease with a somatic UBA1 variant: expanding spectrum of autoinflammatory phenotypes of VEXAS syndrome. Clin Immunol 238:108996. https:\/\/doi.org\/10.1016\/j.clim.2022.108996","journal-title":"Clin Immunol"},{"key":"3193_CR15","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.3324\/haematol.2021.279418","volume":"106","author":"M Hage-Sleiman","year":"2021","unstructured":"Hage-Sleiman M, Lalev\u00e9e S, Guermouche H, Favale F, Chaquin M, Battistella M et al (2021) Dominance of an UBA1 mutant clone over a CALR mutant clone: from essential thrombocytemia to VEXAS. Haematologica 106:3245\u20133248. https:\/\/doi.org\/10.3324\/haematol.2021.279418","journal-title":"Haematologica"},{"key":"3193_CR16","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1038\/s41375-021-01353-8","volume":"35","author":"LP Zhao","year":"2021","unstructured":"Zhao LP, Schell B, S\u00e9bert M, Kim R, Lemaire P, Boy M et al (2021) Prevalence of UBA1 mutations in MDS\/CMML patients with systemic inflammatory and auto-immune disease. Leukemia 35:2731\u20132733. https:\/\/doi.org\/10.1038\/s41375-021-01353-8","journal-title":"Leukemia"},{"key":"3193_CR17","doi-asserted-by":"publisher","first-page":"678927","DOI":"10.3389\/fimmu.2021.678927","volume":"12","author":"F Staels","year":"2021","unstructured":"Staels F, Betrains A, Woei-A-Jin FJSH, Boeckx N, Beckers M, Bervoets A et al (2021) Case report: VEXAS syndrome: from mild symptoms to life-threatening macrophage activation syndrome. Front Immunol 12:678927. https:\/\/doi.org\/10.3389\/fimmu.2021.678927","journal-title":"Front Immunol"},{"key":"3193_CR18","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1007\/s10875-021-01070-y","volume":"41","author":"A Grey","year":"2021","unstructured":"Grey A, Cheong PL, Lee FJ, Abadir E, Favaloro J, Yang S et al (2021) A case of VEXAS syndrome complicated by hemophagocytic lymphohistiocytosis. J Clin Immunol 41:1648\u20131651. https:\/\/doi.org\/10.1007\/s10875-021-01070-y","journal-title":"J Clin Immunol"},{"issue":"22","key":"3193_CR19","doi-asserted-by":"publisher","first-page":"00181","DOI":"10.1016\/j.jaad.2022.01.042","volume":"S0190\u20139622","author":"D Sterling","year":"2022","unstructured":"Sterling D, Duncan ME, Philippidou M, Salisbury JR, Kulasekararaj AG, Basu TN (2022) VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) for the dermatologist. J Am Acad Dermatol S0190\u20139622(22):00181\u201300185. https:\/\/doi.org\/10.1016\/j.jaad.2022.01.042","journal-title":"J Am Acad Dermatol"},{"issue":"137","key":"3193_CR20","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1182\/blood.2020010286","volume":"1","author":"JA Poulter","year":"2021","unstructured":"Poulter JA, Collins JC, Cargo C, De Tute RM, Evans P, Ospina Cardona D et al (2021) Novel somatic mutations in UBA1 as a cause of VEXAS syndrome. Blood 1(137):3676\u20133681. https:\/\/doi.org\/10.1182\/blood.2020010286","journal-title":"Blood"},{"key":"3193_CR21","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1136\/annrheumdis-2021-220089","volume":"80","author":"N Tsuchida","year":"2021","unstructured":"Tsuchida N, Kunishita Y, Uchiyama Y, Kirino Y, Enaka M, Yamaguchi Y et al (2021) Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis. Ann Rheum Dis 80:1057\u20131061. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220089","journal-title":"Ann Rheum Dis"},{"key":"3193_CR22","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jaci.2021.05.014","volume":"149","author":"CI van der Made","year":"2022","unstructured":"van der Made CI, Potjewijd J, Hoogstins A, Willems HPJ, Kwakernaak AJ, de Sevaux RGL et al (2022) Adult-onset autoinflammation caused by somatic mutations in UBA1: a Dutch case series of patients with VEXAS. J Allergy Clin Immunol 149:432-439.e4. https:\/\/doi.org\/10.1016\/j.jaci.2021.05.014","journal-title":"J Allergy Clin Immunol"},{"key":"3193_CR23","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1001\/jamadermatol.2021.3344","volume":"157","author":"E Zakine","year":"2021","unstructured":"Zakine E, Schell B, Battistella M, Vignon-Pennamen MD, Chasset F, Mah\u00e9vas T et al (2021) UBA1 variations in neutrophilic dermatosis skin lesions of patients with VEXAS syndrome. JAMA Dermatol 157:1349\u20131354. https:\/\/doi.org\/10.1001\/jamadermatol.2021.3344","journal-title":"JAMA Dermatol"},{"key":"3193_CR24","doi-asserted-by":"publisher","first-page":"002484","DOI":"10.12890\/2021_002484","volume":"8","author":"A Himmelmann","year":"2021","unstructured":"Himmelmann A, Br\u00fccker R (2021) The VEXAS syndrome: uncontrolled inflammation and macrocytic anaemia in a 77-year-old male patient. Eur J Case Rep Intern Med 8:002484. https:\/\/doi.org\/10.12890\/2021_002484","journal-title":"Eur J Case Rep Intern Med"},{"key":"3193_CR25","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1093\/rheumatology\/keab225","volume":"60","author":"A Oganesyan","year":"2021","unstructured":"Oganesyan A, Jachiet V, Chasset F, Hirsch P, Hage-Sleiman M, Fabiani B et al (2021) VEXAS syndrome: still expanding the clinical phenotype. Rheumatology (Oxford) 60:e321\u2013e323. https:\/\/doi.org\/10.1093\/rheumatology\/keab225","journal-title":"Rheumatology (Oxford)"},{"key":"3193_CR26","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1182\/blood.2020010177","volume":"137","author":"E Bourbon","year":"2021","unstructured":"Bourbon E, Heiblig M, Gerfaud Valentin M, Barba T, Durel CA, Lega JC et al (2021) Therapeutic options in VEXAS syndrome: insights from a retrospective series. Blood 137:3682\u20133684. https:\/\/doi.org\/10.1182\/blood.2020010177","journal-title":"Blood"},{"key":"3193_CR27","doi-asserted-by":"publisher","first-page":"e435","DOI":"10.1111\/jdv.17924","volume":"36","author":"T Khosravi-Hafshejani","year":"2022","unstructured":"Khosravi-Hafshejani T, O\u2019Connor M, To F, Sreenivasan G, Shojania K, Au S (2022) The spectrum of skin disease in VEXAS syndrome: a report of a novel clinico-histopathologic presentation. J Eur Acad Dermatol Venereol 36:e435\u2013e437. https:\/\/doi.org\/10.1111\/jdv.17924","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3193_CR28","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1080\/03009742.2022.2045791","volume":"51","author":"E Mart\u00edn-Nares","year":"2022","unstructured":"Mart\u00edn-Nares E, Vargas-Seraf\u00edn C, Delgado-de la Mora J, Montante-Montes de Oca D, Grayson PC, Larios E, Crisp\u00edn JC (2022) Orbital and periorbital inflammation in VEXAS syndrome. Scand J Rheumatol 51:338\u2013341. https:\/\/doi.org\/10.1080\/03009742.2022.2045791","journal-title":"Scand J Rheumatol"},{"key":"3193_CR29","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1053\/j.seminhematol.2021.10.006","volume":"58","author":"EM Groarke","year":"2021","unstructured":"Groarke EM, Dulau-Florea AE, Kanthi Y (2021) Thrombotic manifestations of VEXAS syndrome. Semin Hematol 58:230\u2013238. https:\/\/doi.org\/10.1053\/j.seminhematol.2021.10.006","journal-title":"Semin Hematol"},{"key":"3193_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15858","author":"L Khider","year":"2022","unstructured":"Khider L, Templ\u00e9 M, Bally C, Spaeth A, Darnige L, Sanchez O et al (2022) Systematic search for the UBA1 mutation in men after a first episode of venous thromboembolism: a monocentric study. J Thromb Haemost. https:\/\/doi.org\/10.1111\/jth.15858","journal-title":"J Thromb Haemost"},{"key":"3193_CR31","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1136\/jnnp-2021-327949","volume":"93","author":"C Bert-Marcaz","year":"2021","unstructured":"Bert-Marcaz C, Briantais A, Faucher B, Corazza G, Ebbo M, Attarian S et al (2021) Expanding the spectrum of VEXAS syndrome: association with acute-onset CIDP. J Neurol Neurosurg Psychiatry 93:797\u2013798. https:\/\/doi.org\/10.1136\/jnnp-2021-327949","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3193_CR32","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1002\/art.41743","volume":"73","author":"MA Ferrada","year":"2021","unstructured":"Ferrada MA, Sikora KA, Luo Y, Wells KV, Patel B, Groarke EM et al (2021) Somatic mutations in UBA1 define a distinct subset of relapsing polychondritis patients with VEXAS. Arthritis Rheumatol 73:1886\u20131895. https:\/\/doi.org\/10.1002\/art.41743","journal-title":"Arthritis Rheumatol"},{"key":"3193_CR33","doi-asserted-by":"publisher","first-page":"e002255","DOI":"10.1136\/rmdopen-2022-002255","volume":"8","author":"MY Khitri","year":"2022","unstructured":"Khitri MY, Guedon AF, Georgin-Lavialle S, Terrier B, Saadoun D, Seguier J et al (2022) Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients. RMD Open 8:e002255. https:\/\/doi.org\/10.1136\/rmdopen-2022-002255","journal-title":"RMD Open"},{"key":"3193_CR34","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/bjh.17679","volume":"195","author":"V Lacombe","year":"2021","unstructured":"Lacombe V, Prevost M, Bouvier A, Th\u00e9pot S, Chabrun F, Kosmider O et al (2021) Vacuoles in neutrophil precursors in VEXAS syndrome: diagnostic performances and threshold. Br J Haematol 195:286\u2013289. https:\/\/doi.org\/10.1111\/bjh.17679","journal-title":"Br J Haematol"},{"key":"3193_CR35","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1053\/j.seminhematol.2021.10.001","volume":"58","author":"JA Poulter","year":"2021","unstructured":"Poulter JA, Savic S (2021) Genetics of somatic auto-inflammatory disorders. Semin Hematol 58:212\u2013217. https:\/\/doi.org\/10.1053\/j.seminhematol.2021.10.001","journal-title":"Semin Hematol"},{"key":"3193_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/art.42101","author":"C Campochiaro","year":"2022","unstructured":"Campochiaro C, Tomelleri A, Grassini G, Cangi MG, Cavalli G, De Luca G et al (2022) Successful use of cyclosporin A and interleukin-1 blockers combination in VEXAS syndrome: a single-centre case series. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.42101","journal-title":"Arthritis Rheumatol"},{"key":"3193_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jdcr.2022.02.022","volume":"23","author":"A Goyal","year":"2022","unstructured":"Goyal A, Narayanan D, Wong W, Laga AC, Connell NT, Ritter SY et al (2022) Tocilizumab for treatment of cutaneous and systemic manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndrome. JAAD Case Rep 23:15\u201319. https:\/\/doi.org\/10.1016\/j.jdcr.2022.02.022","journal-title":"JAAD Case Rep"},{"key":"3193_CR38","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/imj.15742","volume":"52","author":"S Islam","year":"2022","unstructured":"Islam S, Cullen T, Sumpton D, Damodaran A, Heath D, Bosco A et al (2022) VEXAS syndrome: lessons learnt from an early Australian case series. Intern Med J 52:658\u2013662. https:\/\/doi.org\/10.1111\/imj.15742","journal-title":"Intern Med J"},{"key":"3193_CR39","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1182\/bloodadvances.2021004749","volume":"6","author":"A Diarra","year":"2022","unstructured":"Diarra A, Duployez N, Fournier E, Preudhomme C, Coiteux V, Magro L et al (2022) Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience. Blood Adv 6:998\u20131003. https:\/\/doi.org\/10.1182\/bloodadvances.2021004749","journal-title":"Blood Adv"},{"key":"3193_CR40","doi-asserted-by":"publisher","first-page":"901063","DOI":"10.3389\/fimmu.2022.901063","volume":"13","author":"Y Kunishita","year":"2022","unstructured":"Kunishita Y, Kirino Y, Tsuchida N, Maeda A, Sato Y, Takase-Minegishi K et al (2022) Case report: tocilizumab treatment for VEXAS syndrome with relapsing polychondritis: a single-center, 1-year longitudinal observational study in Japan. Front Immunol 13:901063. https:\/\/doi.org\/10.3389\/fimmu.2022.901063","journal-title":"Front Immunol"},{"key":"3193_CR41","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/blood.2022016642","volume":"140","author":"M Heiblig","year":"2022","unstructured":"Heiblig M, Ferrada MA, Koster MJ, Barba T, Gerfaud-Valentin M, M\u00e9kinian A et al (2022) Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. Blood 140:927\u2013931. https:\/\/doi.org\/10.1182\/blood.2022016642","journal-title":"Blood"},{"key":"3193_CR42","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/bjh.17893","volume":"196","author":"T Comont","year":"2022","unstructured":"Comont T, Heiblig M, Rivi\u00e8re E, Terriou L, Rossignol J, Bouscary D et al (2022) Azacitidine for patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry. Br J Haematol 196:969\u2013974. https:\/\/doi.org\/10.1111\/bjh.17893","journal-title":"Br J Haematol"},{"key":"3193_CR43","doi-asserted-by":"publisher","first-page":"e174","DOI":"10.1093\/rheumatology\/keac054","volume":"61","author":"K Pathmanathan","year":"2022","unstructured":"Pathmanathan K, Taylor E, Balendra J, Lim A, Carroll G (2022) VEXAS syndrome: favourable clinical and partial haematological responses to subcutaneous abatacept therapy with 30-month follow-up. Rheumatology (Oxford) 61:e174\u2013e177. https:\/\/doi.org\/10.1093\/rheumatology\/keac054","journal-title":"Rheumatology (Oxford)"},{"key":"3193_CR44","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41409-021-01544-y","volume":"57","author":"M Loschi","year":"2022","unstructured":"Loschi M, Roux C, Sudaka I, Ferrero-Vacher C, Marceau-Renaut A, Duployez N et al (2022) Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report. Bone Marrow Transplant 57:315\u2013318. https:\/\/doi.org\/10.1038\/s41409-021-01544-y","journal-title":"Bone Marrow Transplant"},{"key":"3193_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18424","author":"N van Leeuwen-Kerkhoff","year":"2022","unstructured":"van Leeuwen-Kerkhoff N, de Witte MA, Heijstek MW, Leavis HL (2022) Case report: Up-front allogeneic stem cell transplantation in a patient with the VEXAS syndrome. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.18424","journal-title":"Br J Haematol"},{"key":"3193_CR46","doi-asserted-by":"publisher","first-page":"926500","DOI":"10.3389\/fmed.2022.926500","volume":"9","author":"A Vitale","year":"2022","unstructured":"Vitale A, Caggiano V, Della Casa F, Hern\u00e1ndez-Rodr\u00edguez J, Frassi M, Monti S et al (2022) Development and implementation of the AIDA international registry for patients with VEXAS syndrome. Front Med (Lausanne) 9:926500. https:\/\/doi.org\/10.3389\/fmed.2022.926500","journal-title":"Front Med (Lausanne)"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-023-03193-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-023-03193-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-023-03193-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T19:09:28Z","timestamp":1680894568000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-023-03193-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["3193"],"URL":"https:\/\/doi.org\/10.1007\/s11739-023-03193-z","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,20]]},"assertion":[{"value":"11 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author(s) declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The realization of this review did not foresee any intervention on humans or animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"No computation on patients\u2032 data was performed. Images involving VEXAS patients were included in this review after having obtained the informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}